

3 February 2023

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Annual General Meeting

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today gives notice that its Annual General Meeting ("AGM") will be held at 10:00am GMT on 27 February 2023 at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES.

The Notice of AGM will be sent to shareholders today and can also be viewed on the "Investors" section of the Company's website at www.oncimmune.com.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOANKNBQDBKDCBK